Clinical Trials Browser

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03141684 2026-06-03

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Phase 2 Active not recruiting

63 enrolled 1 FDA

Sarcoma

Sarcoma, Alveolar Soft Part

NCT03587311 2026-06-03

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

96 enrolled

Gynecologic

Fallopian Tube Endometrioid Adenocarcinoma

NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

65 enrolled

Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05211323 2026-06-03

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Liver Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2 Recruiting

156 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06325683 2026-06-03

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Suspended

184 enrolled

CNS

Glioblastoma

NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Phase 2 Not yet recruiting

87 enrolled

Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT03660826 2026-06-02

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT02971501 2026-05-29

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

5 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

42 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

11 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Phase 2 Recruiting

27 enrolled

Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase 2 Active not recruiting

54 enrolled 12 charts

Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Phase 2 Active not recruiting

59 enrolled

CNS

Astrocytoma, Glioblastoma

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Tocilizumab for Patients With Cancer and COVID-19 Disease

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Mel47

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer